We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
- Authors
Raje, Noopur S.; Cohen, Adam D.; Patel, Krina K.; de Donk, Niels W.C.J. van; Richter, Joshua; San-Miguel, Jesus
- Abstract
The 20th annual IMS meeting dedicated a session to the practical aspects regarding T-cell redirected therapies, specifically chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies/T-cell engagers (bsAbs/TCEs), an increasing number of which have been introduced recently into the relapsed/refractory MM (RRMM) treatment landscape. This article summarizes the discussions and key take-home messages from this session. Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2024, Vol 24, Issue 6, p350
- ISSN
2152-2650
- Publication type
Article
- DOI
10.1016/j.clml.2024.03.005